Pharmacodynamics. Betamethasone dipropionate is a potent corticosteroid. when applied topically, it has a quick and long-term anti-inflammatory, anti-allergic, and vasoconstrictor effect.
Local treatment with corticoids is not etiotropic; in case of discontinuation of therapy, a relapse of the disease is possible.
Salicylic acid, due to its keratolytic and exfoliating properties, makes the lower layers of the skin available for the action of betamethasone dipropionate and improves its absorption.
Pharmacokinetics. Absorption of betamethasone dipropionate is possible mainly after long-term treatment with application to a large surface of the skin.
Topical treatment of dermatoses sensitive to corticosteroids, such as chronic, erythematous or hyperkeratotic psoriasis and other dermatoses of an erythematous-squamous nature, such as seborrheic dermatitis (eczema), dry eczema in the desquamative phase, lichenification.
The ointment is applied in a thin layer on the entire affected area of the skin 2 times a day, in the morning and in the evening, and allowed to penetrate into the skin, which is easily massaged at the same time. for some patients, a single daily application may be sufficient to achieve a satisfactory result.
The maximum daily dose should be gradually reduced to as low as possible to control symptoms.
The preparation is contraindicated in patients with hypersensitivity to active substances or any other component of the preparation.
Also, the preparation is contraindicated in bacterial and viral infections, such as syphilitic and tuberculous skin lesions; post-vaccination reactions, smallpox, chickenpox, herpes simplex, shingles, perioral dermatitis, perianal itching and itching of the genitals, widespread plaque psoriasis, varicose veins, diaper dermatitis, molluscum contagiosum, dermatacea fungi, acupuncture.
When using local corticosteroids, the following side reactions may occur: burning sensation, itching, irritation, dry skin, skin tingling, skin tightening, skin cracking, warm sensation, lamellar peeling of the skin, focal skin peeling, erythema, telangiectasia, folliculitis, hypertrichosis, acne-like rash , hypopigmentation, perioral dermatitis and allergic contact dermatitis.
When using the preparation over a large area or under an occlusive dressing, especially over a long period, it is necessary to keep in mind the possibility of developing a systemic effect of the preparation.
In persons with individual intolerance to the components of the preparation, hypersensitivity reactions are possible.
Any side effects noted with the systemic use of glucocorticoids, including suppression of the adrenal cortex, can also occur with local application of GCS.
The following adverse reactions may occur more frequently with occlusive dressings: skin maceration, secondary infection, skin atrophy, stretch marks and prickly heat.
Stretch marks and vasodilation, mainly on the face, can be the result of prolonged continuous application of the preparation.
The preparation is not intended for use in ophthalmology. avoid contact with eyes, mucous membranes, wound surfaces and ulcers.
If skin irritation or signs of hypersensitivity appear, treatment should be discontinued and the patient should be appropriately treated.
Any side effects that occur with the use of systemic corticosteroids, including inhibition of the function of the adrenal cortex, can also be observed with local administration of GCS, especially in children.
Systemic absorption of topical corticosteroids increases with an increase in the area of the treated body surface or with the use of occlusive dressings. In such cases or with prolonged use, appropriate measures should be taken.
Corticosteroids with high activity over large areas of the skin should be used under close and periodic monitoring, as they can cause depression of the hypothalamic-pituitary-adrenal system. If depression develops, the preparation should be canceled, the frequency of application should be reduced or the patient should be switched to a weaker corticosteroid preparation.
The function of the hypothalamic-pituitary-adrenal system, as a rule, is restored when the preparation is discontinued. In some cases, withdrawal symptoms may develop, which require the addition of a systemic corticosteroid.
With the disappearance of dandruff or keratinization, treatment is continued only with corticosteroids.
The use of the preparation under occlusive dressings is not recommended.
If excessive dryness occurs or if skin irritation increases, the use of the preparation should be discontinued.
Topical corticosteroids can cause psoriasis for a variety of reasons, including recurrence of symptoms followed by the development of tolerance, the risk of pustular psoriasis, and local systemic toxicity due to a decrease in the protective function of the skin. Patients with impaired liver function are more sensitive to systemic exposure. Careful observation of the patient is necessary.
In the presence of infection, antifungal or antibacterial agents should be prescribed, respectively. If the desired effect does not occur quickly, the use of corticosteroids should be discontinued until signs of infection are eliminated.
Appropriate measures should be taken to prevent an increase in the absorption area when using the preparation on damaged areas, atrophied skin, large areas of the body surface, under occlusive dressings or in children (due to an increase in the ratio of "body surface area / body weight"). When applied to large areas of the body surface, the absorption of salicylic acid must also be taken into account.
Topical corticosteroids can distort the clinical picture.
Relapse is possible if treatment is interrupted, as well as exacerbation of infection and delayed healing.
The preparation should not be applied to mucous membranes or areas around the eyes due to the keratolytic action of salicylic acid.
Application of the preparation to areas with atrophied skin is contraindicated.
Use during pregnancy and lactation. Should not be used in the first trimester of pregnancy.
Due to the fact that the safety of the use of topical corticosteroids in pregnant women has not been established, the appointment of these preparations is possible only if the expected benefit to the expectant mother clearly outweighs the potential threat to the fetus. Preparations in this group are contraindicated in pregnant women in high doses and for a long time.
To date, it has not been established whether corticosteroids, when applied topically, as a result of systemic absorption, can penetrate into breast milk, therefore, when prescribing the preparation, a decision should be made to stop breastfeeding.
Children. There are no clinical data on the use of the preparation in children, therefore it is undesirable to use it in patients of this age category.
Since the ratio of surface area to body weight in children is greater than in adults, they have a more active absorption of the preparation. Therefore, children are more prone to the development of suppression of the function of the hypothalamic-pituitary-adrenal system due to the use of corticosteroids and the development of exogenous effects of corticosteroids.
In children who received topical corticosteroids, adrenal suppression, Cushing's syndrome, growth retardation, insufficient body weight gain, and increased intracranial pressure were noted.
Manifestations of suppression of the function of the adrenal cortex: low levels of cortisol in the blood plasma and lack of response to a test with stimulation of the adrenal glands using ACTH preparations. Increased intracranial pressure is manifested by protrusion of the fontanelle, headache, bilateral edema of the optic nerve head.
Since corticosteroids can interfere with the production of growth hormones in children, it is necessary to monitor the body weight and growth of patients in the pediatric population.
Cases of interaction with other preparations are unknown.
Topical application of salicylic acid should not be combined with oral administration of preparations containing acetylsalicylic acid and other NSAIDs. Do not use in conjunction with benzoyl peroxide and topical retinoids. Salicylic acid can increase the permeability of the skin to other topical preparations and thereby increase their absorption into the body. In addition, salicylic acid can enhance the undesirable effect of methotrexate and the hypoglycemic effect of oral antidiabetic preparations - sulfonylurea derivatives. If the patient is taking any other medications, be sure to inform the doctor about it.
With prolonged or excessive use of local corticosteroids, it is possible to suppress the pituitary-adrenal function with the development of secondary adrenal insufficiency and the appearance of symptoms of hypercortisolism, including Cushing's disease. Excessive or prolonged use of topical salicylic acid preparations can lead to symptoms of salicism.
Treatment. Appropriate symptomatic therapy is prescribed. Symptoms of acute hypercortisolism are usually reversible. If necessary, the electrolyte balance is corrected. In the case of chronic toxic effects, it is recommended to gradually withdraw corticosteroids.
Treatment of salicism is symptomatic. Measures are taken to remove salicylates from the body more quickly. In case of overgrowth of resistant microorganisms, it is recommended to stop treatment with the preparation and prescribe the necessary therapy. Sodium bicarbonate is used orally to alkalize urine and increase urine output.
In its original packaging at a temperature not exceeding 25 ° C.
There are no reviews for this product.